Zhongzhi Pharmaceutical (HKG:3737) said its net profit is expected to fall by more than 70% in 2025 from a year earlier, according to a Jan. 23 Hong Kong bourse filing.

Shares of the firm were down over 5% in Monday morning trade.

The company said the decline was mainly driven by short-term revenue pressure following adjustments in industry policies, which weighed on sales and profitability.